2 Information about the technologies

2.1

The technologies included in this early value assessment use artificial intelligence (AI) algorithms to assist the opportunistic detection of vertebral fragility fractures (VFFs) on X-ray images and CT scans involving the spine. They are intended to be used as decision aids for healthcare professionals interpreting the X‑ray or CT scan.

2.2

Some companies provide the software directly, whereas others provide it through multivendor platforms. The technologies use X‑ray or CT scans in digital imaging and communications in medicine (DICOM) format, which are stored on the hospital's picture archiving and communications system (PACS).

2.3

Different technologies report and display results in different ways including as annotated images within PACS Viewers, DICOM Secondary Captures or through standalone applications. Some also have notifications or summary reports. The technologies included in this assessment are shown in table 1.

Table 1 Artificial intelligence technologies
Technology (company) CE mark Population Image type Compatible imaging

Annalise Enterprise CXR/Annalise Container CXR (Annalise.AI)

Class IIb

People 16 years and over

Chest X-ray

Anterior–posterior, posterior–anterior or lateral view

BoneView
(Gleamer)

Class IIa

People over 2 years

Spinal X-ray

Appendicular skeleton, ribs and thoracic-lumbar spine

TechCare Spine
(Milvue)

Class IIa

Not reported

Spinal
X-ray

Thoracic or lumbar spine lateral views

BriefCase-Triage
(Aidoc Medical)

Class IIa

People 18 years and over

CT

Chest, abdominal

CINA-VCF Quantix (Avicenna.AI)

Class IIb

People 50 years and over

CT

Chest, abdominal

HealthVCF
(Nanox AI)

Class IIa

People 50 years and over

CT

Chest, abdominal pelvic showing T1 to L5

HealthOST
(Nanox AI)

Class IIa

People 50 years and over

CT

Chest, abdominal pelvic showing T1 to L4

IB Lab FLAMINGO
(IB Lab)

Class IIa

People 50 years and over

CT

Thoracic or lumbar spine

2.4

Some of the technologies have additional functionalities, such as vertebral labelling, bone mass density assessment, prioritisation tools or the ability to detect other pathologies. This early value assessment has assessed the clinical and cost effectiveness of the technologies only for the opportunistic detection of VFFs.